100 related articles for article (PubMed ID: 1301588)
1. BCG treatment in Tis of the urinary bladder, results of the EORTC Protocol 30861. EORTC GU Group.
Jakse G; Hall R; Bono A; Höltl W; Carpentier P; de Pauw M; Sylvester R
Prog Clin Biol Res; 1992; 378():69-74. PubMed ID: 1301588
[No Abstract] [Full Text] [Related]
2. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer.
Sosnowski JT
Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653
[No Abstract] [Full Text] [Related]
3. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
Brosman S
Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
[No Abstract] [Full Text] [Related]
4. Intravesical instillation of BCG in carcinoma in situ of the urinary bladder. EORTC protocol 30861. EORTC-GU Group.
Jakse G
Prog Clin Biol Res; 1989; 310():187-92. PubMed ID: 2771992
[TBL] [Abstract][Full Text] [Related]
5. Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group.
Bouffioux C
Scand J Urol Nephrol Suppl; 1991; 138():167-77. PubMed ID: 1838428
[No Abstract] [Full Text] [Related]
6. [Our experience in the treatment of superficial cancer of the bladder with BCG].
Martínez E; Díaz I; Salvador J; Viladoms JM; Zungri E; Solé-Balcells FJ
Arch Esp Urol; 1989 May; 42(4):325-7. PubMed ID: 2782959
[TBL] [Abstract][Full Text] [Related]
7. Bacillus Calmette-Guérin immunotherapy. Techniques and results.
Brosman SA
Urol Clin North Am; 1992 Aug; 19(3):557-64. PubMed ID: 1636239
[TBL] [Abstract][Full Text] [Related]
8. BCG for bladder cancer.
Med Lett Drugs Ther; 1991 Apr; 33(841):29-30. PubMed ID: 2002783
[No Abstract] [Full Text] [Related]
9. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
[No Abstract] [Full Text] [Related]
10. A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.
Brosman SA; Lamm DL; van der Meijden AP; Debruyne FM
Prog Clin Biol Res; 1989; 310():311-23. PubMed ID: 2672019
[TBL] [Abstract][Full Text] [Related]
11. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.
Lamm DL; Crissmann J; Blumenstein B; Crawford ED; Montie J; Scardino P; Grossman HB; Stanisic T; Smith J; Sullivan J
Prog Clin Biol Res; 1989; 310():263-70. PubMed ID: 2672016
[No Abstract] [Full Text] [Related]
12. BCG vaccine in urinary bladder cancer.
Brosman SA
West J Med; 1991 Dec; 155(6):633. PubMed ID: 1812634
[No Abstract] [Full Text] [Related]
13. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
Debruyne FM; van der Meijden AP; Franssen MP
Prog Clin Biol Res; 1989; 303():435-46. PubMed ID: 2506556
[No Abstract] [Full Text] [Related]
14. Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst).
Barreto L; Csizer Z; Sparkes JD
Dev Biol Stand; 1992; 77():229-31. PubMed ID: 1426667
[TBL] [Abstract][Full Text] [Related]
15. BCG in carcinoma in situ and superficial bladder tumors.
Lamm DL
Prog Clin Biol Res; 1988; 269():497-510. PubMed ID: 3293069
[No Abstract] [Full Text] [Related]
16. Multicenter study of the BCG Tokyo strain for intravesical treatment in patients with superficial bladder cancer. BCG Study Group.
Aso Y; Akaza H; Kameyama S; Niijima T
Prog Clin Biol Res; 1989; 303():383-91. PubMed ID: 2675000
[No Abstract] [Full Text] [Related]
17. Management of superficial transitional cell carcinoma of the bladder.
Fleischmann J; Goldberg G
Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of carcinoma in situ of the urinary bladder with BCG].
Schnyder von Wartensee M; Ackermann D; Studer UE; Zingg EJ
Helv Chir Acta; 1989 Aug; 56(3):351-4. PubMed ID: 2807965
[TBL] [Abstract][Full Text] [Related]
19. [Topical BCG therapy of in situ cancer of the urinary bladder].
Mack D; Jakse G
Urologe A; 1987 Jan; 26(1):22-5. PubMed ID: 3576860
[TBL] [Abstract][Full Text] [Related]
20. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
